Hitoji Uchiyama: Influence Statistics

Hitoji Uchiyama

Hitoji Uchiyama

Department of Hematology, Japanese Red Cross Kyoto Daiichi Hospital, Kyoto, Japan; | Department of Hematology, Japanese Red Cross Kyoto Daiichi Hospital, Kyoto, Japan | ...

Hitoji Uchiyama: Expert Impact

Concepts for which Hitoji Uchiyama has direct influence: Multiple myeloma , Large bcell , Cell lymphoma , Prognostic impact , Platelet engraftment , Cell transplantation , Diffuse large .

Hitoji Uchiyama: KOL impact

Concepts related to the work of other authors for which for which Hitoji Uchiyama has influence: Multiple myeloma , Acute myeloid leukemia , Stem cell , Intraocular pressure , Peripheral blood , Flt3 inhibitors , Stimulating factor .

KOL Resume for Hitoji Uchiyama

Year
2022

Department of Hematology, Japanese Red Cross Kyoto Daiichi Hospital, Kyoto, Japan;

2021

Department of Hematology, Japanese Red Cross Kyoto Daiichi Hospital, Kyoto, Japan.

2020

Department of Hematology, Japan Red Cross Kyoto Daiichi Hospital, Kyoto, Japan

2019

Department of Hematology, Japanese Red Cross Kyoto Daiichi Hospital, Kyoto, Japan;, View further author information

2018

Kansai Myeloma Forum, Japan

2017

Department of Hematology, Kyoto First Red Cross Hospital, Honmachi, Higashiyama-ku, 605-0981, Kyoto, Japan

2016

Department of Hematology, Japanese Red Cross Kyoto Daini Hospital, Kyoto, Japan.

2015

Division of Hematology, Department of Medicine, Kyoto Second Red Cross Hospital, Kyoto, Japan

2013

Kyoto Second Red Cross Hospital Division of Hematology Department of Medicine Kyoto Japan

2012

Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine, 465 Kajii-cho, Kamigyo-ku, 602-8566, Kyoto, Japan

2011

Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine, Kyoto, and, Department of Pathology and Clinical Laboratories, Nagoya University Hospital, Nagoya, Japan

2010

Department of Molecular Hematology and Oncology, Kyoto Prefectural University of Medicine, Graduate School of Medical Science, Kyoto, Japan

2009

Division of Hematology and Oncology, Department of Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan

Department of Molecular‐Targeting Cancer Prevention

2006

Department of Internal Medicine, Nantan General Hospital, Kyoto, Japan

2005

Department of Medicine, Nantan General Hospital, Yagi, Japan

2004

Department of Medicine, Nantan General Hospital

1997

Second Department of Medicine, Kyoto Prefectural University of Medicine, Kyoto, Japan

The Department of Internal Medicine, Kumihama Municipal Hospital

1994

Second Department of Medicine, Kyoto Prefectural University of Medicine, Kyoto

Prominent publications by Hitoji Uchiyama

KOL-Index: 10589 . PURPOSE: beta-catenin is the downstream effector of the Wnt signaling pathway, and it regulates cell proliferation. beta-catenin overexpression correlates positively with prognosis in several types of malignancies. We herein assessed its effects on growth of multiple myeloma cells using a xenograft model. EXPERIMENTAL DESIGN: We first investigated the expression of beta-catenin in multiple ...
Known for Multiple Myeloma | Small Interfering | Mouse Model | Beta Catenin
KOL-Index: 8870 . PURPOSE: To evaluate intraocular pressure (IOP) change through hemodialysis and examine other factors to affect IOP change in patients treated with hemodialysis. DESIGN: Prospective, observational case series. METHODS: IOP, blood pressure, and plasma colloid osmotic pressure (COP) were measured in 188 eyes of 95 patients receiving hemodialysis in Nantan General Hospital. RESULTS: IOP ...
Known for Intraocular Pressure | Hemodialysis Patients | Renal Dialysis | Iop Blood
KOL-Index: 8359 . In the opinion of the European LeukemiaNet (ELN), nucleophosmin member 1 gene mutation (NPM1 mut)-positive acute myeloid leukemia (AML) with an fms-like kinase 3-internal tandem duplication (FLT3-ITD) allele ratio (AR) <0.5 (low AR) has a favorable prognosis, and allogeneic hematopoietic stem cell transplant (allo-HSCT) in the first complete remission (CR1) period is not actively ...
Known for Prognostic Impact | Myeloid Leukemia | Npm1 Mutation | Allohsct Cr1
KOL-Index: 8172 . Recently, the ligand for c-mpl has been cloned and initial studies have shown it to be the platelet regulatory factor, thrombopoietin (TPO). To elucidate the role of TPO in the reconstitution of megakaryopoiesis and platelet production after stem cell transplantation, we measured serum TPO levels in nine patients undergoing autologous peripheral blood stem cell transplantation (PBSCT) and ...
Known for Stem Cell | Thrombopoietin Levels | Platelet Count | Autologous Peripheral
KOL-Index: 7777 . To improve the selection of donors for allogeneic stem cell transplantation, it is important to identify reliable parameters that predict CD34+-cell yields after granulocyte-colony stimulating factor (G-CSF)-induced peripheral blood stem cell (PBSC) mobilization. We retrospectively investigated the peripheral blood (PB) kinetics of white blood cells (WBCs), CD34+ cells, matrix ...
Known for Stem Cell | Peripheral Blood | Stimulating Factor | Granulocyte Colony
KOL-Index: 7740 . Autologous hematopoietic cell transplantation (HCT) has not gained universal popularity in the treatment of acute myeloid leukemia (AML), and its status remains unclear. To determine the implementation status and outcomes of autologous HCT for adults with AML in Japan, we analyzed data from 1,174 patients (including 446 with acute promyelocytic leukemia [APL]) who underwent autologous HCT ...
Known for Acute Myeloid Leukemia | Cell Transplantation | Autologous Hematopoietic | Myeloid Aml
KOL-Index: 7699 . High-dose chemotherapy (HDT) supported by autologous stem cell transplantation (ASCT) has long been one of the standards of care for younger patients with multiple myeloma (MM). Cyclophosphamide (CY) plus granulocyte colony-stimulating factor (G-CSF) has been the conventional preparation for hematopoietic progenitor cell (HPC) mobilization, although the optimal dosage of CY in this setting ...
Known for Multiple Myeloma | Cell Mobilization | Stimulating Factor | Granulocyte Colony
KOL-Index: 7226 . Therapy-related acute myeloid leukemia and myelodysplastic syndrome (t-AML/MDS) represent severe late effects in patients receiving hematopoietic cell transplantation (HCT) for lymphoma. The choice between high-dose therapy with autologous HCT and allogeneic HCT with reduced-intensity conditioning remains controversial in patients with relapsed lymphoma. We retrospectively analyzed ...
Known for Myelodysplastic Syndrome | Autologous Hct | Cell Transplantation | Acute Myeloid
KOL-Index: 6571 . OBJECTIVE: We retrospectively investigated the efficacy and predictive factors for the treatment outcomes of bortezomib plus dexamethasone (BD) as second-line induction therapy prior to high-dose chemotherapy supported by autologous stem cell transplantation (HDT/ASCT) in multiple myeloma (MM) patients. METHODS: Sixty-six transplant eligible MM patients treated by the Kyoto Clinical ...
Known for Multiple Myeloma | Stem Cell | Induction Therapy | Partial Response
KOL-Index: 6385 . We conducted a multicenter prospective study for evaluating the utility and prognostic markers of recombinant human soluble thrombomodulin (rTM) treatment for acute disseminated intravascular coagulation (DIC) by various types of hematologic malignancies. The study comprised 30 patients with DIC due to hematologic diseases without severe infection. DIC improved in 15 patients and 20 were ...
Known for Disseminated Intravascular | Rtm Dic | Adamts13 Activity | Human Soluble
KOL-Index: 6200 . Subcutaneous panniculitis-like T cell lymphoma (SPTL) is a rare subtype of non-Hodgkin lymphoma for which a definitive therapeutic strategy has not been established yet. We report a case of chemotherapy-resistant SPTL with hemophagocytic syndrome (HPS) which was successfully treated with cyclosporine A (CsA) plus methylprednisolone (mPSL), and also reviewed 11 SPTL cases treated with CsA, ...
Known for Cell Lymphoma | Hemophagocytic Syndrome | Subcutaneous Panniculitis | 2 Weeks
KOL-Index: 6106 . The prognostic significance of FLT3-tyrosine kinase domain (TKD) mutations remains unknown. To investigate the prognostic impact of FLT3-TKD, 676 de novo acute myeloid leukemia (AML), we retrospectively analyzed cases and conducted a review of the literature. Of the 676 de novo AML cases, 34 (5.0%) were FLT3-TKD-positive; both FLT3-TKD and FLT3-ITD were noted in only two cases (0.3%). ...
Known for Tyrosine Kinase | Acute Myeloid | Flt3 Tkd | Prognostic Significance
KOL-Index: 6043 . INTRODUCTION: The most common cause of central pontine myelinolysis is an overly rapid correction of hyponatremia, although it can also occur in patients with any condition leading to nutritional or electrolyte stress. We report a case of diffuse large B-cell lymphoma with central pontine myelinolysis developing at the onset of disease. To the best of our knowledge, hematological ...
Known for Central Pontine | Cell Lymphoma | Diffuse Large | Resonance Imaging

Key People For Multiple Myeloma

Top KOLs in the world
#1
Kenneth Carl Anderson
multiple myeloma mm cells board directors
#2
Robert A Kyle
multiple myeloma undetermined significance consultancy funding
#3
Sundararajan Vincent Rajkumar
multiple myeloma consultancy funding undetermined significance
#4
Paul Gerard Guy Richardson
multiple myeloma board directors advisory committees
#5
JesusFernando San San Miguel
multiple myeloma consultancy honoraria board directors
#6
Bart Barlogie
multiple myeloma total therapy gene expression

Department of Hematology, Japanese Red Cross Kyoto Daiichi Hospital, Kyoto, Japan; | Department of Hematology, Japanese Red Cross Kyoto Daiichi Hospital, Kyoto, Japan | Department of Hematology, Japanese Red Cross Kyoto Daiichi Hospital, Kyoto, Japan